Creative Medical Technology (NASDAQ:CELZ) Stock Passes Below Fifty Day Moving Average – Time to Sell?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shares crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.98 and traded as low as $1.75. Creative Medical Technology shares last traded at $1.86, with a volume of 37,374 shares traded.

Analyst Upgrades and Downgrades

CELZ has been the subject of several recent research reports. Wall Street Zen downgraded Creative Medical Technology from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Creative Medical Technology currently has a consensus rating of “Reduce”.

Creative Medical Technology Stock Performance

The company has a market capitalization of $4.80 million, a price-to-earnings ratio of -0.64 and a beta of 2.09. The company has a 50 day moving average price of $1.98 and a 200 day moving average price of $2.72.

Institutional Trading of Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is owned by institutional investors and hedge funds.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.